Showing results (31-40 of 52) with videos related to
Sort By:
Pageof 6
Lancet (London, England)|September 14, 2023
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trialZev A Wainberg, Davide Melisi, Teresa Macarulla, et al.Frontiers in Immunology|June 24, 2022
Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In VivoPilar M Lanuza, M Henar Alonso, Sandra Hidalgo, et al.The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.Plos One|October 3, 2012
Prognostic role of host cyclooxygenase and cytokine genotypes in a Caucasian cohort of patients with gastric adenocarcinomaMaría Asunción García-González, David Nicolás-Pérez, Angel Lanas, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2024
A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR TrialFrancesca Sarno, Jair Tenorio, Sofia Perea, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649Markus Moehler, Hong Xiao, Steven I Blum, et al.The Oncologist|November 16, 2024
Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 studyPilar García-Alfonso, Paula Jimenez-Fonseca, Javier Soto-Alsar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumabCarlos Gomez-Martin, Jose Carlos Plaza, Roberto Pazo-Cid, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2024
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 TrialYelena Y Janjigian, Jaffer A Ajani, Markus Moehler, et al.British Journal of Cancer|September 7, 2016
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancerAngus G Dalgleish, Justin Stebbing, Douglas Ja Adamson, et al.Pageof 6